10-K: Larimar Therapeutics Reports Positive Data, Targets BLA Submission for Nomlabofusp by Year-End 2025

Larimar Therapeutics advances nomlabofusp, a potential treatment for Friedreich's ataxia, with positive clinical data and a targeted BLA submission by the end of 2025.

Summary

• Larimar Therapeutics is focused on developing treatments for rare diseases, with its lead candidate, nomlabofusp, targeting Friedreich's ataxia (FA).
• Nomlabofusp is designed to increase frataxin (FXN) levels in FA patients.
• The company completed Phase 1 and Phase 2 dose exploration trials and has an ongoing Phase 2 OLE trial and a PK run-in study in adolescent patients.
• Phase 2 data showed dose-dependent increases in FXN levels in evaluated tissues.
• The FDA selected nomlabofusp for participation in the START Pilot Program.
• Initial OLE data showed nomlabofusp was generally well tolerated, with injection site reactions being the most common adverse events.
• Long-term tissue FXN levels showed positive mean change from baseline, increasing from 15% of healthy volunteers (HV) at baseline to 30% in buccal cells and from 16% to 72% in skin cells at Day 90.
• The company is increasing the dose in the OLE to 50 mg of nomlabofusp daily.
• The Safety Monitoring Team has deemed anaphylaxis as an adverse drug reaction likely associated with nomlabofusp, and the OLE protocol was amended to administer premedication for the first month of dosing.
• The FDA is open to considering FXN concentration as a reasonably likely surrogate endpoint (RLSE).
• The company is targeting a BLA submission by the end of 2025.
• A global Phase 3 study is on track to initiate by mid-2025.
• As of December 31, 2024, the company had $183.5 million in cash, cash equivalents, and marketable securities, expected to fund operations into the second quarter of 2026.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. Positive clinical data and regulatory progress are encouraging, but the company's lack of revenue, ongoing losses, and the potential need for additional funding create uncertainty. The anaphylaxis adverse event is a concern, but the company is taking steps to mitigate the risk.

Positives

• Phase 2 data showed dose-dependent increases in FXN levels in evaluated tissues.
• Long-term tissue FXN levels showed positive mean change from baseline, increasing from 15% of healthy volunteers (HV) at baseline to 30% in buccal cells and from 16% to 72% in skin cells at Day 90.
• The FDA is open to considering FXN concentration as a reasonably likely surrogate endpoint (RLSE).
• The company is targeting a BLA submission by the end of 2025.
• As of December 31, 2024, the company had $183.5 million in cash, cash equivalents, and marketable securities, expected to fund operations into the second quarter of 2026.
• The FDA selected nomlabofusp for participation in the START Pilot Program.
• The company received access to the MHRA Innovative Licensing and Access Pathway (ILAP) for the treatment of adults and children with FA.

Negatives

• The Safety Monitoring Team has deemed anaphylaxis as an adverse drug reaction likely associated with nomlabofusp, and the OLE protocol was amended to administer premedication for the first month of dosing.
• The company has incurred significant losses since its inception and anticipates continued losses for the foreseeable future.
• The company has no commercial revenue and may never become profitable.

Risks

• The company's success is dependent on the success of nomlabofusp.
• Clinical development is a lengthy and expensive process with an uncertain outcome.
• The company may experience difficulties identifying and enrolling patients in clinical trials.
• Nomlabofusp may cause adverse events or undesirable side effects.
• The company intends to pursue accelerated approval from the FDA, but this may not lead to a faster process or increase the likelihood of approval.
• The company may need to raise additional funding to complete the development and commercialization of nomlabofusp.
• The company may infringe the intellectual property rights of others.
• The company is subject to stringent and evolving U.S. and foreign laws, regulations and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security.

Future Outlook

The company plans to continue discussions with the FDA regarding the adequacy of the safety data set for a BLA submission seeking accelerated approval targeted for year-end 2025 and is on track to initiate a global Phase 3 study by mid-2025.

Management Comments

• FDA acknowledged that frataxin deficiency appears to be critical to the pathogenic mechanism of FA, and that there continues to be an unmet need for treatments for FA patients that address the underlying disease pathophysiology.
• FDA stated in written correspondence associated with a meeting through the START pilot program that they are open to considering the use of FXN concentration as an RLSE and the acceptability of FXNs use as an RLSE would ultimately be a matter of review of the data in a future marketing application.

Industry Context

The biopharmaceutical industry is characterized by intense competition to develop new technologies and proprietary therapies. Larimar faces competition from companies like Biogen, Design Therapeutics, Lexeo Therapeutics, Neurocrine Biosciences/Voyager Therapeutics and PTC Therapeutics, all developing therapeutics to treat FA.

Comparison to Industry Standards

• Larimar is developing nomlabofusp, a protein replacement therapy for Friedreich's Ataxia (FA).
• A comparable company is Biogen, which has already received FDA and European Commission approval for SKYCLARYS TM (omaveloxolone) for the treatment of FA in adults and adolescents aged 16 and older.
• PTC Therapeutics has an NDA accepted for filing by the FDA for vatiquinone for the treatment of children and adults living with FA with a target action date of August 19, 2025.
• Larimar is targeting a BLA submission by the end of 2025, which would be later than Biogen's approved therapy and potentially later than PTC Therapeutics' vatiquinone if approved.

Related Party Transactions

• The Company entered into an agreement with the Friedreichs Ataxia Research Alliance (FARA) to join the TRACK-FA Neuroimaging Consortium and incurred $0.9 million of costs related to the Track-FA program.
• The Company sponsored patient and caregiver awareness events held by FARA for a cumulative $0.1 million.

Stakeholder Impact

• Positive clinical data and regulatory progress are encouraging for patients with Friedreich's ataxia.
• The potential for anaphylaxis is a concern for patients participating in clinical trials.
• The company's financial stability is important for employees and investors.

Next Steps

• Continue discussions with FDA regarding the adequacy of the safety data set for a BLA submission seeking accelerated approval targeted for year-end 2025.
• Initiate the global Phase 3 study by mid-2025.
• Provide an update on OLE data on at least 30 to 40 study participants in September 2025.

Key Dates

Keywords

nomlabofusp, Friedreichs ataxia, FXN, clinical trials, FDA, rare diseases, biotechnology, accelerated approval, START Pilot Program, MHRA ILAP, protein replacement therapy